RCS - Yourgene Health PLC - Opening of new Yourgene Health Canada facilities

Yourgene HealthAnnouncement

19/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220119:nRSS8831Ya&default-theme=true

RNS Number : 8831Y  Yourgene Health PLC  19 January 2022

 

Yourgene Health plc

("Yourgene" or the "Company")

 

Opening of new Yourgene Health Canada Inc. facilities

Supporting future growth for Ranger® Technology

 

Manchester, UK - 19 January 2022: Yourgene (AIM: YGEN), the international
molecular diagnostics group, announces that Yourgene Health Canada Inc. will
launch its new expanded facilities at 702 - 1515 Broadway Street, Port
Coquitlam, Vancouver, BC V3C 6M2, today from 12:30 (PST).

 

The opening will be led by Mayor Brad West, Mayor of Port Coquitlam and will
include a tour of the facilities followed by speeches and a lunch for those in
attendance. The new facilities are four times the square footage of the former
location and will be well suited for the expected growth in the Company's
instrument manufacturing and consumable shipping requirements. Yourgene took
over the facilities in December 2021 following an increased headcount by 120%
over 2021 and the Company is currently involved in a hiring plan that will add
another six team members by April 2022.

 

Coastal Genomics Inc. has been renamed Yourgene Health Canada Inc. following
the acquisition in August 2020, to further integrate Coastal Genomics into the
larger Yourgene Health group of companies.

 

Lyn Rees, Chief Executive Officer, commented: 'We are delighted to be in our
new facilities, which will truly support the scale up of manufacturing of our
Ranger® Technology platforms, reagents and consumables to support our growing
global customer base."

 

 Yourgene Health plc                              Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Singer Capital Markets (Joint Corporate Broker)  Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                               Tel: +44 (0)20 7710 7600
 Nicholas Moore / Matthew Blawat / Ben Maddison

 Walbrook PR Ltd (Media and Investor Relations)   Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
 Paul McManus / Alice Woodings                    Mob: 07980 541 893 / 07407 804 654

 

 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops
integrated genomic technologies and services enabling precision medicine. The
group works in partnership with global leaders in DNA technology to advance
diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global
laboratory service network equipped to be a full life-cycle partner for
clinical, research and pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop, manufacture, obtain
regulatory approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID testing
service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com (http://www.yourgene-health.com/) and follow us on
twitter @Yourgene_Health.

 

Reach is a non-regulatory news service. By using this service an issuer is
confirming that the information contained in this announcement is of a
non-regulatory nature. Information required to be notified under the AIM Rules
for Companies, Market Abuse Regulation or other regulation would be
disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZGMMZRVGZZZ